NISCI - Nogo Inhibition in Spinal Cord Injury

  • STATUS
    Recruiting
  • End date
    Dec 30, 2023
  • participants needed
    114
  • sponsor
    University of Zurich
Updated on 2 May 2021

Summary

The purpose of the NISCI trial is to test if an antibody therapy can improve movement and quality of life of tetraplegic patients. A previous trial showed this treatment is safe and well accepted. This is a placebo controlled, randomized, double blind, multicenter, multinational study to assess the safety, tolerability, feasibility and preliminary efficacy of early (within 4-28 days post injury) initiation of treatment with repeated bolus injections of NG-101 in cervical acute SCI patients. The study has 3 phases: screening/baseline Phase, treatment phase, and a follow-up phase.

The study design will allow simultaneous enrolment of patients with complete or incomplete SCI. Enrolment and stratification of the patients is based and individualized prediction of upper limb outcomes.

For further information please visit NISCI website: https://nisci-2020.eu

Details
Condition Acute Spinal Cord Injury, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, Spinal Cord Injury, Acute, spinal cord injury acute
Treatment placebos, NG-101
Clinical Study IdentifierNCT03935321
SponsorUniversity of Zurich
Last Modified on2 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Acute cervical spinal cord injury (SCI) (Neurological level of injury C1-C8 with confirmed classification of ASIA impairment scale (AIS) A-D at screening and predicted upper extremities motor score (UEMS) recovery of less than 41/50 (according to the URP prediction model)
-28 days post-injury
No required mechanical ventilation or patients that not completely depend on mechanical ventilation
Hemodynamically and clinical stable patient according to the acute SCI condition at baseline
Written informed consent
Cooperation and willingness to complete all aspects of the study
Ability of subject to understand character and individual consequences of the study

Exclusion Criteria

Complete anatomical transection confirmed by magnetic resonance imaging (MRI)
Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
Major brachial or lumbar plexus damage/trauma
Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
Other significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastorintestinal, cardiac, immunodeficiency (including anamnestic known HIV) or kidney disease; or active malignancy
History of or an acute episode of Guillain-Barre syndrome
History of recent (6 months) meningitis or meningoencephalitis
History of refractory epilepsy
History of or current autoimmune disease
Patients with uncontrolled bleeding diathesis and/or who require concomitant treatment with coumarin anticoagulant
Presence of any unstable medical or psychiatric condition
Drug dependence any time during the 6 month's preceding study entry
Pregnant or nursing women
History of a life-threatening allergic or immune mediated reaction
Patients with the presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
Patients who are unconscious
History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note